Announcements
CV6 Announces Initiation of Patient Dosing in CV6-168 Phase 1a Clinical Trial
CV6 Therapeutics (NI) Ltd. (“CV6”) today announced the successful dosing of the second patient in its Phase 1a study evaluating CV6-168 + infusional 5-fluorouracil (5-FU) in cancer patients.
CV6 to Present Details of Ongoing Phase 1a Clinical Trial at 2024 ASCO Annual Meeting
CV6 Therapeutics (‘CV6’) will be presenting details of their ongoing CV6-168 Phase 1a clinical trial at the 2024 ASCO Annual Meeting to be held at McCormick Pace in Chicago, USA on May 31st to June 4th.